<?xml version='1.0' encoding='utf-8'?>
<document id="24186263"><sentence text="Assessment of interaction potential of AZD2066 using in vitro metabolism tools, physiologically based pharmacokinetic modelling and in vivo cocktail data." /><sentence text="Static and dynamic (PBPK) prediction models were applied to estimate the drug-drug interaction (DDI) risk of AZD2066"><entity charOffset="109-116" id="DDI-PubMed.24186263.s2.e0" text="AZD2066" /></sentence><sentence text=" The predictions were compared to the results of an in vivo cocktail study" /><sentence text=" Various in vivo measures for tolbutamide as a probe agent for cytochrome P450 2C9 (CYP2C9) were also compared"><entity charOffset="30-41" id="DDI-PubMed.24186263.s4.e0" text="tolbutamide" /></sentence><sentence text="" /><sentence text="In vitro inhibition data for AZD2066 were obtained using human liver microsomes and CYP-specific probe substrates" /><sentence text=" DDI prediction was performed using PBPK modelling with the SimCYP simulator™ or static model" /><sentence text=" The cocktail study was an open label, baseline, controlled interaction study with 15 healthy volunteers receiving multiple doses of AD2066 for 12 days" /><sentence text=" A cocktail of single doses of 100 mg caffeine (CYP1A2 probe), 500 mg tolbutamide (CYP2C9 probe), 20 mg omeprazole (CYP2C19 probe) and 7"><entity charOffset="38-46" id="DDI-PubMed.24186263.s9.e0" text="caffeine" /><entity charOffset="70-81" id="DDI-PubMed.24186263.s9.e1" text="tolbutamide" /><entity charOffset="104-114" id="DDI-PubMed.24186263.s9.e2" text="omeprazole" /><entity charOffset="116-123" id="DDI-PubMed.24186263.s9.e3" text="CYP2C19" /><pair ddi="false" e1="DDI-PubMed.24186263.s9.e0" e2="DDI-PubMed.24186263.s9.e0" /><pair ddi="false" e1="DDI-PubMed.24186263.s9.e0" e2="DDI-PubMed.24186263.s9.e1" /><pair ddi="false" e1="DDI-PubMed.24186263.s9.e0" e2="DDI-PubMed.24186263.s9.e2" /><pair ddi="false" e1="DDI-PubMed.24186263.s9.e0" e2="DDI-PubMed.24186263.s9.e3" /><pair ddi="false" e1="DDI-PubMed.24186263.s9.e1" e2="DDI-PubMed.24186263.s9.e1" /><pair ddi="false" e1="DDI-PubMed.24186263.s9.e1" e2="DDI-PubMed.24186263.s9.e2" /><pair ddi="false" e1="DDI-PubMed.24186263.s9.e1" e2="DDI-PubMed.24186263.s9.e3" /><pair ddi="false" e1="DDI-PubMed.24186263.s9.e2" e2="DDI-PubMed.24186263.s9.e2" /><pair ddi="false" e1="DDI-PubMed.24186263.s9.e2" e2="DDI-PubMed.24186263.s9.e3" /></sentence><sentence text="5 mg midazolam (CYP3A probe) was simultaneously applied at baseline and during the administration of AZD2066"><entity charOffset="5-14" id="DDI-PubMed.24186263.s10.e0" text="midazolam" /><entity charOffset="101-108" id="DDI-PubMed.24186263.s10.e1" text="AZD2066" /><pair ddi="false" e1="DDI-PubMed.24186263.s10.e0" e2="DDI-PubMed.24186263.s10.e0" /><pair ddi="false" e1="DDI-PubMed.24186263.s10.e0" e2="DDI-PubMed.24186263.s10.e1" /></sentence><sentence text=" Bupropion as a CYP2B6 probe (150 mg) and 100 mg metoprolol (CYP2D6 probe) were administered on separate days"><entity charOffset="1-10" id="DDI-PubMed.24186263.s11.e0" text="Bupropion" /><entity charOffset="49-59" id="DDI-PubMed.24186263.s11.e1" text="metoprolol" /><pair ddi="false" e1="DDI-PubMed.24186263.s11.e0" e2="DDI-PubMed.24186263.s11.e0" /><pair ddi="false" e1="DDI-PubMed.24186263.s11.e0" e2="DDI-PubMed.24186263.s11.e1" /></sentence><sentence text=" The pharmacokinetic parameters for the probe drugs and their metabolites in plasma and urinary recovery were determined" /><sentence text="" /><sentence text="In vitro AZD2066 inhibited CYP1A2, CYP2B6, CYP2C9, CYP2C19 and CYP2D6" /><sentence text=" The static model predicted in vivo interaction with predicted AUC ratio values of &gt;1" /><sentence text="1 for all CYP (except CYP3A4)" /><sentence text=" The PBPK simulations predicted no risk for clinical relevant interactions" /><sentence text=" The cocktail study showed no interaction for the CYP2B6 and CYP2C19 enzymes, a possible weak inhibition of CYP1A2, CYP2C9 and CYP3A4 activities and a slight inhibition (29 %) of CYP2D6 activity" /><sentence text=" The tolbutamide phenotyping metrics indicated that there were significant correlations between CLform and AUCTOL, CL, Aemet and LnTOL24h"><entity charOffset="5-16" id="DDI-PubMed.24186263.s19.e0" text="tolbutamide" /></sentence><sentence text=" The MRAe in urine showed no correlation to CLform" /><sentence text="" /><sentence text="DDI prediction using the static approach based on total concentration indicated that AZD20066 has a potential risk for inhibition"><entity charOffset="85-93" id="DDI-PubMed.24186263.s22.e0" text="AZD20066" /></sentence><sentence text=" However, no DDI risk could be predicted when a more in vivo-like dynamic prediction method with the PBPK with SimCYP™ software based on early human PK data was used and more parameters (i" /><sentence text="e" /><sentence text=" free fraction in plasma, no DDI risk) were taken into account" /><sentence text=" The clinical cocktail study showed no or low risks for clinical relevant DDI interactions" /><sentence text=" Our findings are in line with the hypothesis that the dynamic prediction method predicts DDI in vivo in humans better than the static model based on total plasma concentrations" /><sentence text="" /></document>